About Laevoroc Oncology
Laevoroc Oncology is a company based in Hunenberg (Switzerland) founded in 2019 by Davide Guggi.. Laevoroc Oncology has raised $1.1 million across 1 funding round. Laevoroc Oncology offers products and services including LR09, LR06, and LR02. Laevoroc Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Hunenberg, Switzerland
- Founders Davide Guggi
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Laevoroc Oncology Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.1 M (USD)
in 1 rounds
-
Latest Funding Round
$1.1 M (USD), Seed
May 11, 2021
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Laevoroc Oncology
Laevoroc Oncology offers a comprehensive portfolio of products and services, including LR09, LR06, and LR02. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitor targeting relapsed leukemia after stem cell transplantation
Oral prodrug for maintenance therapy in various cancers
Inhibitor for brain cancer treatment with CNS penetration
Unlock access to complete
Unlock access to complete
Funding Insights of Laevoroc Oncology
Laevoroc Oncology has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.1 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $1.1M
-
First Round
First Round
(11 May 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Seed - Laevoroc Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Laevoroc Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Laevoroc Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Laevoroc Oncology Comparisons
Competitors of Laevoroc Oncology
Laevoroc Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Laevoroc Oncology
Frequently Asked Questions about Laevoroc Oncology
When was Laevoroc Oncology founded?
Laevoroc Oncology was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Laevoroc Oncology located?
Laevoroc Oncology is headquartered in Hunenberg, Switzerland. It is registered at Hunenberg, Zug, Switzerland.
Is Laevoroc Oncology a funded company?
Laevoroc Oncology is a funded company, having raised a total of $1.1M across 1 funding round to date. The company's 1st funding round was a Seed of $1.1M, raised on May 11, 2021.
What does Laevoroc Oncology do?
Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.
Who are the top competitors of Laevoroc Oncology?
Laevoroc Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Laevoroc Oncology offer?
Laevoroc Oncology offers LR09, LR06, and LR02.